R

Regeneron Pharmaceuticals

Develops biopharmaceutical therapies for serious diseases

Principal Manufacturing Science and Technology Engineer

Full-TimeUpdated Deadline 11/6/26
$92.2k - $176k/yr
Senior, Expert
Bachelor's, Master's, PhD, Bachelor of Science (BS)
East Greenbush, NY, USA
In PersonOn-site expectations apply; Monday–Friday, 8:00 a.m.–4:30 p.m. Travel: 10–50% domestic, sometimes international.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A BS/BA degree in an engineering-related field, with proven experience or an equivalent combination of education and experience.
  • For Principal Engineer level: a BS/BA in an engineering field with 8+ years of proven experience; an MS with 7+ years; or a PhD with 2 years of experience.
  • For Staff Engineer level: a BS/BA with 10+ years of experience and demonstrated cross-site scientific leadership; an MS with 9+ years; a PhD with 5+ years of experience; or an equivalent combination of education and experience.
Responsibilities
  • Provide technical expertise for internal and external technology transfer of drug substance manufacturing processes, mainly for products utilizing synthetic chemistry and peptides.
  • Generate, review, and support technology-transfer and lifecycle documentation, including process descriptions, master plans, reports, and technical documents.
  • Provide technical support to manufacturing operations during start-up, engineering runs, validation, and routine manufacturing.
  • Apply engineering principles to problem solving and process support.
  • Review manufacturing documentation generated by receiving sites, including batch records, automation recipes, standard operating procedures, and change documentation.
  • Gather, trend, and analyze process data to support process understanding and ongoing process performance monitoring.
  • Participate in investigations and deviation assessments, and support identification of root causes and corrective actions.
  • Work with Manufacturing, Quality, Regulatory, Analytical Sciences, and Engineering teams to execute MSAT tasks on time.
  • Ensure activities align with current Good Manufacturing Practice standards, data integrity expectations, and applicable safety standards.
  • Identify potential technical risks and raise issues with proposed mitigation strategies.
  • Lead defined workstreams for technology transfers or process validation activities, including coordination of cross-functional inputs.
  • Provide technical mentorship to junior engineers.
  • Own and maintain detailed transfer gap assessments and execution plans for sophisticated processes or programs.
  • Define and justify risk-based approaches for process validation, control strategies, and change implementation.
Desired Qualifications
  • A BS in Chemical Engineering or Biochemical Engineering is preferred.
  • Knowledge of biopharmaceutical manufacturing processes and technology transfer principles is a plus.
  • Familiarity with current Good Manufacturing Practice requirements, data integrity principles, and regulated documentation practices is preferred.

About the company

R

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi paid $1 billion upfront, with up to $7 billion more for Regeneron's immunology pipeline.
  • Q2 2026 revenue rose 17% to $4.3 billion; Dupixent sales hit $6.0 billion.
  • Libtayo and EYLEA HD both posted record sales in Q2 2026, widening diversification.

What critics are saying

  • EYLEA biosimilar competition starts in January 2027 after Samsung's settlement.
  • Regeneron faces a 2026 SDNY securities class action over the failed fianlimab melanoma trial.
  • Dupixent's patent cliff later this decade threatens the company's biggest profit pool.

What makes Regeneron Pharmaceuticals unique

  • VelocImmune keeps generating partnered immunology assets; Sanofi renewed the alliance on October 1, 2026.
  • Dupixent remains Regeneron's engine, with over 1.5 million patients across nine indications.
  • EYLEA HD conversion shows platform strength; U.S. sales hit $596 million in Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Wellness Program
  • Paid Vacation
  • Equity Awards
  • Annual Bonuses
  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

1%

1 year growth

12%

2 year growth

12%
Yahoo Finance
Oct 30th, 2026
Regeneron posts record Dupixent, EYLEA HD and Libtayo sales; eyes November FDA decision on cemdisiran

Regeneron Pharmaceuticals reported record quarterly net sales for Dupixent, EYLEA HD, and Libtayo in the third quarter of 2026. It was the third straight quarter of double-digit growth in both revenue and profit. EYLEA HD now makes up nearly two-thirds of the US retinal franchise, with physician demand up 20% sequentially. Libtayo's US sales rose 81%. Regeneron expects a US Food and Drug Administration decision in November on cemdisiran for generalized myasthenia gravis. It would be the first siRNA therapy for the condition. The company expects 2027 research and development spending to rise by a mid-teens percentage to support about 15 Phase 3 trials. It also signalled a shift towards acquiring outside innovation, from early-stage platforms to commercial-stage products. Third quarter Ilaris royalty revenue included a one-off catch-up of about $60 million.

Yahoo Finance
Oct 30th, 2026
Regeneron Q3 revenue jumps 36% to $5.1B as Dupixent and Eylea HD drive growth

Regeneron Pharmaceuticals reported third-quarter revenue of $5.1 billion, up 36% year over year. Non-GAAP diluted earnings per share rose 70% to $20.07, driven by higher Sanofi collaboration revenue and growth in DUPIXENT, EYLEA HD and LIBTAYO. DUPIXENT sold more than $6.5 billion worldwide. EYLEA HD sales rose 62% to $699 million, while legacy EYLEA fell 41% to $400 million amid biosimilar competition. LIBTAYO sales grew 51% to $550 million. The company expects a US Food and Drug Administration decision in November on cemdisiran for generalized myasthenia gravis. It plans more than 15 Phase III trial starts in 2026. Regeneron expects a $1 billion upfront payment from Sanofi in the fourth quarter. It ended the quarter with $16.2 billion in cash and marketable securities, net of debt.

Yahoo Finance
Oct 30th, 2026
Regeneron jumps 13.55% on Q3 earnings beat as revenue climbs 36% to $5.1B

Regeneron shares jumped 13.55% to $929.69 on October 30, 2026, after third-quarter results beat expectations. Non-GAAP earnings per share were $20.07 against a $16.19 consensus estimate, and revenue rose 36% year over year to $5.12 billion. Sanofi collaboration revenue climbed 68% to $2.72 billion. US sales of EYLEA HD rose 62% and Libtayo grew 51%, while the company raised its full-year non-GAAP gross margin guidance to about 86%. The rally lifted sector funds. The Health Care Select Sector SPDR Fund (XLV) gained 1.8% and the iShares Biotechnology ETF (IBB) rose 1.25%. Regeneron expects a US Food and Drug Administration decision on cemdisiran next month.

Yahoo Finance
Oct 30th, 2026
Regeneron Q3 revenue jumps 36% to $5.12B, beating estimates as EPS hits $20.07

Regeneron reported third-quarter revenue of $5.12 billion, up 36.3% from a year earlier and 12.43% above the Zacks Consensus Estimate of $4.55 billion. Earnings per share (EPS) were $20.07, against $11.83 a year ago and a consensus of $16.08. Collaboration revenue rose 52.4% to $3 billion, led by Sanofi at $2.72 billion, up 68.5%. Bayer revenue fell 22.6% to $267 million. Net product sales grew 13.7% to $1.81 billion. Kevzara sales jumped 66% to $255.6 million, while Praluent rose 21% to $260.9 million. Total Dupixent revenue was $6.54 billion, up 34.7%. Regeneron shares gained 11.4% over the past month, compared with 0.7% for the S&P 500 composite.

Yahoo Finance
Oct 30th, 2026
Regeneron shares jump 8% as Q3 revenue surges 36% to $5.12B, beating estimates

Regeneron Pharmaceuticals shares rose more than 8% in premarket trading on Friday after the biotech firm beat third-quarter estimates. If gains hold, the stock would reach its highest level since October 2024. Revenue rose 36% to $5.12 billion, above analyst estimates of $4.56 billion. Adjusted earnings per share climbed 70% to $20.07, against expectations of $16.25. US sales of Eylea HD, its higher-dose retinal disease treatment, rose 62% to $699 million, while sales of the original Eylea fell 41%. Collaboration revenue from Sanofi jumped 68% to $2.72 billion, driven by Dupixent demand. Chief financial officer Christopher Fenimore said the results position Regeneron to deliver "one of our strongest years ever." The company ended September with about $18.86 billion in cash and marketable securities.